ibrutinib
Showing 1 - 25 of 189
Glioblastoma Trial in Cleveland (Ibrutinib, Radiation, Temozolomide (TMZ))
Active, not recruiting
- Glioblastoma
- Ibrutinib
- +2 more
-
Cleveland, OhioCleveland Clinic Taussig Cancer Institute, Case Comprehensive Ca
Jul 13, 2022
Chronic Lymphocytic Leukemia (CLL) Trial in Boston (Ibrutinib, Copanlisib, Acalabrutinib)
Recruiting
- Chronic Lymphocytic Leukemia (CLL)
- Ibrutinib
- +2 more
-
Boston, MassachusettsDana-Farber Cancer Institute
May 13, 2022
Real World Data on Ibrutinib Use in PCNSL Rel/Ref
Recruiting
- PCNSL
- Ibrutinib
-
Milan, ItalyOspedale San Raffaele
Mar 13, 2023
Waldenstrom's Macroglobulinemia Trial in Boston (Ulocuplumab, Ibrutinib)
Active, not recruiting
- Waldenstrom's Macroglobulinemia
- Ulocuplumab
- Ibrutinib
-
Boston, MassachusettsDana Farber Cancer Institute
Jun 20, 2022
Lymphoma, Mantle-Cell, Lymphoma, Lymphoproliferative Disorders Trial (Zilovertamab, Ibrutinib, Placebo)
Not yet recruiting
- Lymphoma, Mantle-Cell
- +7 more
- Zilovertamab
- +2 more
- (no location specified)
Jun 21, 2022
Relapsed/Refractory Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Leukemia Trial in Switzerland (Ibrutinib,
Active, not recruiting
- Relapsed/Refractory Chronic Lymphocytic Leukemia
- +2 more
- Ibrutinib
- Venetoclax
-
Aarau, Switzerland
- +10 more
Mar 10, 2022
Waldenstrom Macroglobulinemia, MYD88 Gene Mutation Trial in Boston (IBRUTINIB, Venetoclax)
Active, not recruiting
- Waldenstrom Macroglobulinemia
- MYD88 Gene Mutation
- IBRUTINIB
- Venetoclax
-
Boston, Massachusetts
- +1 more
Apr 1, 2022
Ependymoma, Medulloblastoma, Glioblastoma Trial in Augusta (Ibrutinib, Indoximod, Cyclophosphamide)
Recruiting
- Ependymoma
- +3 more
- Ibrutinib
- +3 more
-
Augusta, GeorgiaAugusta University, Georgia Cancer Center
Mar 20, 2022
Prostate Cancer Trial in San Francisco, Saint Louis (Ibrutinib, Blood samples for PSA and immune assays, Radical prostatectomy)
Recruiting
- Prostate Cancer
- Ibrutinib
- +2 more
-
San Francisco, California
- +1 more
Aug 15, 2022
Waldenstrom Macroglobulinemia Trial in Austria, Germany, Greece (Carfilzomib + Ibrutinib, Ibrutinib)
Recruiting
- Waldenstrom Macroglobulinemia
- Carfilzomib + Ibrutinib
- Ibrutinib
-
Salzburg, Austria
- +16 more
Mar 11, 2022
Chronic Lymphocytic Leukemia, Loss of Chromosome 17p Trial (Ibrutinib, Venetoclax)
Withdrawn
- Chronic Lymphocytic Leukemia
- Loss of Chromosome 17p
- Ibrutinib
- Venetoclax
- (no location specified)
Oct 29, 2021
Small Lymphocytic Leukemia (SLL), Chronic Lymphocytic Leukemia (CLL) Trial run by the NHLBI (Duvelisib, Ibrutinib)
Terminated
- Small Lymphocytic Leukemia (SLL)
- Chronic Lymphocytic Leukemia (CLL)
- Duvelisib
- Ibrutinib
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Feb 15, 2022
Colon Cancer, Colorectal Cancer, Colorectal Carcinoma Trial in Tampa (Pembrolizumab, Ibrutinib)
Completed
- Colon Cancer
- +3 more
- Pembrolizumab
- Ibrutinib
-
Tampa, FloridaH. Lee Moffitt Cancer Center and Research Institute
Jun 1, 2022
Chronic Lymphocytic Leukemia (CLL) Trial (Venetoclax, Rituximab, Ibrutinib)
Not yet recruiting
- Chronic Lymphocytic Leukemia (CLL)
- Venetoclax
- +2 more
- (no location specified)
Apr 2, 2022
Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma Trial in New York (Ibrutinib, Pembrolizumab)
Recruiting
- Chronic Lymphocytic Leukemia
- Mantle Cell Lymphoma
- Ibrutinib
- Pembrolizumab
-
New York, New YorkIcahn School of Medicine at Mount Sinai
Aug 22, 2022
Graft Vs Host Disease Trial in Atlanta (Rituximab, Ibrutinib)
Recruiting
- Graft Vs Host Disease
- Rituximab
- Ibrutinib
-
Atlanta, GeorgiaNorthside Hospital
Apr 4, 2022
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial run by the NHLBI (Ibrutinib, Fludarabine)
Active, not recruiting
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Ibrutinib
- Fludarabine
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Mar 1, 2022
Lymphoma, Non-Hodgkin Lymphoma, DLBCL Trial run by the National Cancer Institute (NCI) (Venetoclax, Ibrutinib, Prednisone)
Recruiting
- Lymphoma
- +3 more
- Venetoclax
- +4 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Aug 20, 2022
Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell Trial in Whittier (Pirtobrutinib, Ibrutinib)
Recruiting
- Chronic Lymphocytic Leukemia
- +3 more
- Pirtobrutinib
- Ibrutinib
-
Whittier, CaliforniaInnovative Clinical Research Institute
Aug 8, 2022
Refractory Follicular Lymphoma, Relapsed Follicular Lymphoma Trial in Washington, Hackensack, Seattle (Ibrutinib, Venetoclax)
Recruiting
- Refractory Follicular Lymphoma
- Relapsed Follicular Lymphoma
- Ibrutinib
- Venetoclax
-
Washington, District of Columbia
- +2 more
Jul 6, 2022
Chronic Lymphocytic Leukemia Trial in Columbus (biological, drug, other)
Recruiting
- Chronic Lymphocytic Leukemia
- Daratumumab
- +3 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Feb 24, 2022
Metastatic Renal Cell Cancer, Stage IV Renal Cell Cancer Trial in Sacramento (Ibrutinib, Nivolumab)
Completed
- Metastatic Renal Cell Cancer
- Stage IV Renal Cell Cancer
- Ibrutinib
- Nivolumab
-
Sacramento, CaliforniaUniversity of California Davis Comprehensive Cancer Center
Feb 8, 2022
Waldenstrom Macroglobulinemia, Waldenstrom's Disease, Waldenström; Hypergammaglobulinemia Trial in New York (Ibrutinib,
Recruiting
- Waldenstrom Macroglobulinemia
- +6 more
- Ibrutinib
- Daratumumab
-
New York, New YorkWeill Cornell Medicine
Dec 21, 2021
Hematopoietic and Lymphoid Cell Tumor, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma Trial in
Not yet recruiting
- Hematopoietic and Lymphoid Cell Neoplasm
- +5 more
- Ibrutinib
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Jul 10, 2022
Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia Trial in
Active, not recruiting
- Stage I Chronic Lymphocytic Leukemia
- +3 more
- Ibrutinib
- Laboratory Biomarker Analysis
-
Jacksonville, FloridaMayo Clinic in Florida
Mar 24, 2022